NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
P/E ratio for NanoViricides, Inc. (NNVC)
P/E ratio as of 2024: -2.65
According to NanoViricides, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.65. At the end of 2023 the company had a P/E ratio of -1.56.
P/E ratio history for NanoViricides, Inc. from 2005 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -2.65 |
| 2023 | -1.56 |
| 2022 | -2.68 |
| 2021 | -5.68 |
| 2020 | -3.14 |
| 2019 | -2.07 |
| 2018 | -3.34 |
| 2017 | -7.87 |
| 2016 | -8.60 |
| 2015 | -44.51 |
| 2014 | -15.36 |
| 2013 | -3.67 |
| 2012 | -3.86 |
| 2011 | -7.37 |
| 2010 | -14.15 |
| 2009 | -6.74 |
| 2008 | -16.86 |
| 2007 | -9.46 |
| 2006 | -14.33 |
| 2005 | -216.43 |